Cargando…

798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue

BACKGROUND: Para-aminosalicylic acid (PAS) was one of the first antibiotics to be used against tuberculosis (TB) and it is still one of the last remaining drugs available to treat extensively drug-resistant (XDR) disease. Despite being on the market for decades, the mechanism of action of PAS is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Satta, Giovanni, Witney, Adam A, Ere, Diepreye, Disney, Alex, Begum, Neelu, Canseco, Julio Ortiz, Ratledge, Colin, Boa, Andrew N, McHugh, Timothy D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253550/
http://dx.doi.org/10.1093/ofid/ofy210.805
_version_ 1783373521332731904
author Satta, Giovanni
Witney, Adam A
Ere, Diepreye
Disney, Alex
Begum, Neelu
Canseco, Julio Ortiz
Ratledge, Colin
Boa, Andrew N
McHugh, Timothy D
author_facet Satta, Giovanni
Witney, Adam A
Ere, Diepreye
Disney, Alex
Begum, Neelu
Canseco, Julio Ortiz
Ratledge, Colin
Boa, Andrew N
McHugh, Timothy D
author_sort Satta, Giovanni
collection PubMed
description BACKGROUND: Para-aminosalicylic acid (PAS) was one of the first antibiotics to be used against tuberculosis (TB) and it is still one of the last remaining drugs available to treat extensively drug-resistant (XDR) disease. Despite being on the market for decades, the mechanism of action of PAS is not completely understood yet. Sixteen new compounds against Mycobacterium tuberculosis were created in the laboratory as salicylate analogues (based on their chemical structures) and their antimycobacterial activity had never been tested before. The main aim of this project was to test the activity of these new analogues and to understand their mechanism of action (including PAS). METHODS: The compounds were tested using three different methods (spot culture, resazurin, and MGIT system). Additionally, resistant mutants were created against PAS and the most promising analogue; whole-genome sequencing (WGS) was performed to understand their mechanism of action. RESULTS: One compound in particular, AD25a, showed the lowest critical concentration (0.04 µg/mL) among the salicylate analogues. The WGS analysis identified a total of 28 single nucleotide polymorphisms (SNPs) in the AD25a-resistant mutants and 40 SNPs in the PAS-resistant mutants (when compared with the reference strain H37Rv). The SNPs identified in the AD25a and PAS-resistant mutants did not overlap. The genes rrs, rrl and folC were mostly involved in the PAS-resistant mutants. CONCLUSION: The complete difference in the mutation profiles suggests that AD25a has a mechanism of action different to that of PAS, despite AD25a being synthesized as a salicylate analogue. WGS analysis of PAS-resistant mutants has also provided some interesting results. In particular, all our PAS mutants showed mutations in the rrs and rrl genes (16S and 23S RNA genes, respectively). These mutations should affect the ribosomes and the overall synthesis of proteins. This highlights a new potential mechanism of resistance for PAS that has never been observed before. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253550
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62535502018-11-28 798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue Satta, Giovanni Witney, Adam A Ere, Diepreye Disney, Alex Begum, Neelu Canseco, Julio Ortiz Ratledge, Colin Boa, Andrew N McHugh, Timothy D Open Forum Infect Dis Abstracts BACKGROUND: Para-aminosalicylic acid (PAS) was one of the first antibiotics to be used against tuberculosis (TB) and it is still one of the last remaining drugs available to treat extensively drug-resistant (XDR) disease. Despite being on the market for decades, the mechanism of action of PAS is not completely understood yet. Sixteen new compounds against Mycobacterium tuberculosis were created in the laboratory as salicylate analogues (based on their chemical structures) and their antimycobacterial activity had never been tested before. The main aim of this project was to test the activity of these new analogues and to understand their mechanism of action (including PAS). METHODS: The compounds were tested using three different methods (spot culture, resazurin, and MGIT system). Additionally, resistant mutants were created against PAS and the most promising analogue; whole-genome sequencing (WGS) was performed to understand their mechanism of action. RESULTS: One compound in particular, AD25a, showed the lowest critical concentration (0.04 µg/mL) among the salicylate analogues. The WGS analysis identified a total of 28 single nucleotide polymorphisms (SNPs) in the AD25a-resistant mutants and 40 SNPs in the PAS-resistant mutants (when compared with the reference strain H37Rv). The SNPs identified in the AD25a and PAS-resistant mutants did not overlap. The genes rrs, rrl and folC were mostly involved in the PAS-resistant mutants. CONCLUSION: The complete difference in the mutation profiles suggests that AD25a has a mechanism of action different to that of PAS, despite AD25a being synthesized as a salicylate analogue. WGS analysis of PAS-resistant mutants has also provided some interesting results. In particular, all our PAS mutants showed mutations in the rrs and rrl genes (16S and 23S RNA genes, respectively). These mutations should affect the ribosomes and the overall synthesis of proteins. This highlights a new potential mechanism of resistance for PAS that has never been observed before. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253550/ http://dx.doi.org/10.1093/ofid/ofy210.805 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Satta, Giovanni
Witney, Adam A
Ere, Diepreye
Disney, Alex
Begum, Neelu
Canseco, Julio Ortiz
Ratledge, Colin
Boa, Andrew N
McHugh, Timothy D
798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue
title 798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue
title_full 798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue
title_fullStr 798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue
title_full_unstemmed 798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue
title_short 798. The Role of Whole-Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated With Para-Amino Salicylic Acid and Its Analogue
title_sort 798. the role of whole-genome sequencing in characterizing the mechanism of action of anti-tuberculosis compounds: demonstrated with para-amino salicylic acid and its analogue
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253550/
http://dx.doi.org/10.1093/ofid/ofy210.805
work_keys_str_mv AT sattagiovanni 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT witneyadama 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT erediepreye 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT disneyalex 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT begumneelu 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT cansecojulioortiz 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT ratledgecolin 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT boaandrewn 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue
AT mchughtimothyd 798theroleofwholegenomesequencingincharacterizingthemechanismofactionofantituberculosiscompoundsdemonstratedwithparaaminosalicylicacidanditsanalogue